Abstract
Spiroxatrine was identified as a moderately potent (Ki=118 nM) but non‐selective agonist at the human nociceptin/orphanin FQ receptor, ORL1. This compound was subject to chemical modification and one of the resulting compounds, (8‐naphthalen‐1‐ylmethyl‐4‐oxo‐1‐phenyl‐1,3,8‐triaza‐spiro[4.5]dec‐3‐yl)‐acetic acid methyl ester (NNC 63‐0532) was shown to have high affinity for ORL1 (Ki=7.3 nM). NNC 63‐0532 showed only moderate affinity for the following receptors (Ki values in parentheses): μ‐opioid (140 nM), κ‐opioid (405 nM), dopamine D2S (209 nM), dopamine D3 (133 nM) and dopamine D4.4 (107 nM) out of 75 different receptors, ion‐channels and transporters. In functional assays, NNC 63‐0532 was shown to be an agonist at ORL1 (EC50=305 nM), a much weaker agonist at the μ‐opioid receptor (EC50>10 μM) and an antagonist or weak partial agonist at dopamine D2S (IC50=2830 nM). Thus, NNC 63‐0532 is a novel non‐peptide agonist with ∼12 fold selectivity for ORL1 and may be useful for exploring the physiological roles of this receptor owing to its brain‐penetrating properties. British Journal of Pharmacology (2000) 131, 903–908; doi:10.1038/sj.bjp.0703661

This publication has 19 references indexed in Scilit: